China channel feed – Endpoints News

China channel feed

Qiming, Hillhouse bet on Jacobio's nascent pipeline of first-in-class drug hopefuls in $55M round

7 years ago

As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype

7 years ago

Harbour BioMed follows cancer drug deals with a hefty $85M Series B backed by Singapore's GIC

7 years ago

Newborn biobetter, biosimilar maker Mabpharm pitches the latest biotech IPO in Hong Kong

7 years ago

Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report

7 years ago

Right on the heels of $150M raise, Ascentage files the latest in a rush of HKEX biotech IPOs — but is the market too jittery?

7 years ago

Harbour BioMed jumps into the crowded PD-1/L1 race, looking to take a Chinese asset global as checkpoint pipeline bulges

7 years ago

Roche picks up a speedy nod in China as regulators follow through on plans for a fast 48 new drug OKs

7 years ago

Former head of China's FDA booted in wake of searing vaccine scandal as leaders impose 'severe punishment'

7 years ago

Let's go to China: Join Endpoints in Shanghai for the first US-China Biopharma Innovation & Investment Summit — October 22-23 #BIIS18

7 years ago

Publisher's note

Eyes on China stocks: Loncar loads new ETF with his picks for most promising biotechs on HKEX and Nasdaq

7 years ago

Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry

7 years ago

China regulators offer VIP treatment for 48 overseas drugs they're ready to hustle up with accelerated reviews

7 years ago

Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D

7 years ago

BeiGene takes a hit after historic $903M Hong Kong IPO with negative biotech sentiment

7 years ago

Lilly Asian Ventures backs Impact's PARP research again, chipping in for $30M Series C led by Decheng Capital

7 years ago

BeiGene bags a staggering $903M IPO on the HKEX — and still manages to spark some nervous fretting

7 years ago

Ascletis breaks into HKEX, briefly rising on hotly anticipated public debut of first biotech

7 years ago

Fresh out of 6 Dimensions' incubator, Curon launches with $150M and backing from Boyu, Temasek

7 years ago

In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO

7 years ago

Ascletis reaps record $400M from Hong Kong investors in the exchange's first-ever pre-revenue biotech listing

7 years ago

Pre-revenue vaccine developer CanSino lines up at a buzzing HKEX

7 years ago

On its way to making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO

7 years ago

Fast-growing Ascentage has big plans for its latest $150M raise -- but what about the IPO?

7 years ago

First page Previous page 23 24 252627 28 29 Next page Last page